Skip to NavigationSkip to content

Pfizer taps real world evidence for CVD in new partnership

Published on 14/02/18 at 09:23am

BC Platforms, a company that focuses on genomic data managements and analysis, has announced that it has partnered with Pfizer to generate real world evidence (RWE) in atrial fibrillation patients

The collaboration will see BC Platforms analyse anonymised data from Turku University Hospital, in Finland, alongside other health care providers to develop RWE for the use of treating cardiovascular diseases.

Jaakko Parkkinen, Country Medical Director at Pfizer Finland commented, “Cardiovascular diseases are the leading cause of global mortality in the world and the incidence is rising due to an aging population. The diseases are complex and therefore we need data to fully understand and provide the best treatment outcomes for patients. We believe that combining our expertise in treatment of cardiovascular diseases with BC Platforms' advanced genomic and clinical data management solutions […] we can gather and analyse important real world evidence to generate optimal patient outcomes.”

Finland is a country where data analysis and gathering efforts are building, with the FinnGen study launched at the end of 2017 aiming to gather 500,000 unique blood samples to better understand diseases and the development of treatments.

The reason why Finland is becoming a hotbed for genomic analysis was pointed towards in the press release, “Due to the unique heritage of the Finnish population, genomic data can be analysed faster and more effectively than in populations of more heterogeneous origins – significantly improving the chances of breakthrough findings”.

Both Pfizer and BC Platforms are part of this research project, with a number of other pharmaceutical companies providing funds towards the data collection.

BC Platforms has developed a data availability query, meta-analytics and analysis result browsing platform for the FinnGen project to use during research.

Speaking on the company’s current collaboration with Pfizer, Samu Kurki, lead scientist at BC Platforms commented: “Pfizer is one of the leaders in providing treatment solutions for patients suffering from cardiovascular diseases and we are delighted that they have chosen to collaborate with us to support the generation of real world evidence in this space to better understand the complexities of the disease. These types of projects are ideal for leveraging data from innovative healthcare systems to support clinical research and outcomes.”

Ben Hargreaves

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches